¼¼°èÀÇ À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ¼­ºñ½º Á¦°ø¾÷üº°, À¯Åë ä³Îº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Genetic Testing Services Market, By Product Type, By Application, By Service Provider, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1782018
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,557,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,521,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,923,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¼¼°èÀÇ À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 118¾ï 9,756¸¸ ´Þ·¯·Î, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 22.4%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹Ãø

À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - ½ÃÀå ¿ªÇÐ

À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, À¯ÀüÀÚ °úÇÐÀÇ Áøº¸°¡ ÁøÇàµÊ¿¡ µû¶ó, À¯ÀüÀÚ °Ë»ç¿¡ ÀÇÇÑ Á¶±â Áø´ÜÀ̳ª ÁÖ¹®Á¦ Ä¡·áÀÇ ¼±ÅÃÁö¸¦ ¿ä±¸ÇÏ´Â »ç¶÷ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â °Ë»ç ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó, ¿¹¹æ ÇコÄɾ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÓ»óÀû ÀÇ»ç°áÁ¤¿¡ ´ëÇÑ À¯ÀüÇÐÀû ÅëÂûÀÇ ÅëÇÕÀ¸·Î ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)°¡ º¸°íÇϰí ÀÖµíÀÌ À¯Àü¼º ÁúȯÀ̳ª ¼±Ãµ¼º ÀÌ»óÀº ¸ðµç Ãâ»ý¾ÆÀÇ ¾à 2-5%·Î º¸À̸ç, ¼Ò¾Æ°ú ÀÔ¿øÀÇ ÃÖ´ë 30%¿¡ ±â¿©ÇÏ¿© ¼±Áø±¹¿¡¼­ÀÇ ¼Ò¾Æ »ç¸ÁÀÇ ¾à 50%ÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí Â÷¼¼´ë ½ÃÄö½Ì(NGS), CRISPR, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¿¡¼­ÀÇ Çõ½ÅÀÇ ¹ßÀüÀº ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ °Ë»ç ¹× Àåºñ¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ ÀÇÇϸé, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â)¿¡ ¾à 22.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â ½Å»ý¾Æ ½ºÅ©¸®´×ÀÌ 2024³â ÃÖ´ë ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.

¼­ºñ½º Á¦°ø¾÷üº°·Î´Â º´¿ø ¹× Áø·á¼Ò°¡ 2024³â ÁÖ¿ä ¼­ºñ½º Á¦°ø¾÷ü°¡ µÇ¾ú½À´Ï´Ù.

À¯Åë ä³Îº°·Î´Â ¿Â¶óÀÎÀÌ 2024³â ÁÖ¿ä À¯Åë ä³ÎÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâÀ» À̲ø¾ú½À´Ï´Ù.

À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ¼¼°è ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ¼­ºñ½º Á¦°ø¾÷ü, À¯Åë ä³Î, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çüº°·Î Ãâ»ý Àü °Ë»ç, ½Å»ý¾Æ ½ºÅ©¸®´×, ¿¹Ãø ¹× Á¶Á¶ °Ë»ç, ÆÄ¸¶ÄÚÀ¯ÀüüÇÐ °Ë»ç, ±âŸ À¯ÇüÀ¸·Î ºÐ·ùµË´Ï´Ù. ½Å»ý¾Æ ½ºÅ©¸®´×Àº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ½Å»ý¾Æ ½ºÅ©¸®´×Àº Ãâ»ý Á÷ÈÄÀÇ À¯Àü¼º Áúȯ, ´ë»ç¼º Áúȯ, ¼±Ãµ¼º ÁúȯÀÇ Á¶±â ¹ß°ß¿¡ ÇʼöÀûÀÎ ±â´ÉÀ̱⠶§¹®¿¡ À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß´Â ½Å¼ÓÇÑ Áø´Ü°ú ½Ã±â ÀûÀýÇÑ Ä¡·á¸¦ ÃËÁøÇϰí Àå±âÀûÀÎ ÇÕº´Áõ°ú Ä¡¸íÀûÀÎ »çŸ¦ ¿¹¹æÇϱâ À§ÇØ ¼¼°è °¢±¹ÀÇ Á¤ºÎ ¹× ÀÇ·á ±â°üÀÌ ÀÌ·¯ÇÑ °ËÁøÀ» Àǹ«È­Çϰųª °­·ÂÈ÷ ±ÇÀåÇϱ⠶§¹®¿¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÅÄ´ý Áú·®ºÐ¼®¹ýÀ̳ª Â÷¼¼´ë ½ÃÄö½Ì¹ý µîÀÇ À¯ÀüÀÚ °Ë»ç¹ý¿¡ °üÇÑ ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ½Å»ý¾Æ ½ºÅ©¸®´×ÀÇ Á¤¹Ðµµ¿Í ÆøÀÌ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó Á¾¾çÇÐ, °¨¿°,ÀÚ°¡ ¸é¿ª Áúȯ, ±âŸ ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. ¾Ï ¿µ¿ª¿¡¼­ÀÇ À¯ÀüÀÚ °Ë»ç´Â À¯Àü¼º ¾Ï ÁõÈıºÀÇ °ËÃâ, Á¾¾çÀÇ Æ¯ÀÌÀû º¯ÀÌÀÇ °ËÃâ, Ç¥Àû Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀÇ Æò°¡¸¦ ¿ëÀÌÇÏ°Ô ÇÔÀ¸·Î½á, Ä¡·á ¼ºÀûÀ» ´ëÆø Çâ»ó½Ãŵ´Ï´Ù. Á¾¾çÇп¡ À̾î, Àü¿°º´ ºÐ¾ß´Â ƯÈ÷ COVID-19 ÆÒµ¥¹Í°ú °°Àº ¼¼°è °Ç°­»ó ÀÀ±Þ »óȲ¿¡¼­ Á¤È®ÇÏ°í ½Å¼ÓÇÑ º´¿øÃ¼ÀÇ °ËÃâ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç´Â °³ÀÎÀÇ °¨¼ö¼ºÀ» ÆÄ¾ÇÇÏ°í ¸é¿ª Á¶Àý Ä¡·á¸¦ ¸ÂÃãÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ ÀÚ°¡¸é¿ª Áúȯµµ ½ÃÀå¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±âŸ Ä«Å×°í¸®¿¡´Â ½ÉÇ÷°ü Áúȯ, ½Å°æ Áúȯ ¹× Èñ±Í À¯Àüº´°ú °ü·ÃµÈ ¾ÖÇø®ÄÉÀ̼ÇÀÌ Æ÷ÇԵǾî ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áúº´Àº ÀÎÁöµµ¿Í Áø´Ü ´É·ÂÀÇ ¹ßÀü¿¡ µû¶ó Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¼­ºñ½º Á¦°ø¾÷üº°·Î º´¿ø ±â¹Ý °Ë»ç½Ç, Áø´Ü½ÇÇè½Ç, Àü¹® Ŭ¸®´Ð µî 3°³ÀÇ ¹üÁÖ·Î ºÐÇҵ˴ϴÙ. º´¿ø ±â¹Ý °Ë»ç ½Ã¼³Àº ½ÃÀå ¼ºÀåÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. À¯Àü °Ë»ç ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº ÁÖ·Î º´¿ø ¹× Áø·á¼ÒÀ̸ç, ÀÌ·¯ÇÑ ½Ã¼³Àº ±¤¹üÀ§ÇÑ ÀÎÇÁ¶ó, ÃÖ÷´Ü Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¾×¼¼½º, ȯÀÚÀÇ ÄÉ¾î °æ·Î¿ÍÀÇ ¿øÈ°ÇÑ ÅëÇÕ µîÀÇ ÀÌÁ¡À» ´©¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼³Àº Áø´Ü Æò°¡¸¦ ¹Þ´Â °³ÀÎÀÇ ÃÖÃÊÀÇ Ã¢±¸°¡ µÇ´Â °æ¿ì°¡ ¸¹°í, ¾Ï, Èñ±ÍÁúȯ, Ãâ»ý Àü ÀÌ»ó µîÀÇ À¯Àü¼º ÁúȯÀÇ ½Å¼ÓÇÑ ¼Ò°³¿Í °Ë»ç¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. º´¿ø ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡, ¸ÂÃãÇü ÀÇ·á äÅà Áõ°¡, À¯ÀüÀÚ °Ë»ç Á¦°ø¾÷ü¿ÍÀÇ Á¦ÈÞ´Â ½ÃÀå¿¡¼­ ÀÌ ºÎ¹®ÀÇ ¸®´õ½ÊÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº À¯Åë ä³Îº°·Î ¿Â¶óÀΰú ¿ÀÇÁ¶óÀÎ ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. ¿Â¶óÀÎ ºÎ¹®Àº ½ÃÀå ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù. ¿Â¶óÀÎ ºÎ¹®Àº À¯Àü °Ë»ç ¼­ºñ½º ½ÃÀåÀÇ È®´ë¿¡ Å©°Ô ±â¿©Çϰí Àִµ¥, ÀÌ´Â ÁÖ·Î ¼ÒºñÀÚ Á÷Á¢ °Ë»ç(DTC)¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ±× ÆíÀǼº°ú Á¢±ÙÀÇ ¿ëÀ̼º ¶§¹®ÀÔ´Ï´Ù. ¿Â¶óÀÎ Ç÷§ÆûÀ» ÅëÇØ »ç¿ëÀÚ´Â Áý¿¡ ¸Ó¹«¸£¸é¼­ °Ë»ç ŰƮ¸¦ ÁÖ¹®Çϰí, »ùÇÃÀ» äÃëÇϰí, µðÁöÅÐ µ¥ÀÌÅÍ·Î °á°ú¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. À¯ÀüÀû °Ç°­, °¡°è, Áúº´ À§Çè¿¡ °üÇÑ ¼ÒºñÀÚÀÇ ÀǽÄÀÌ ³ô¾ÆÁö¸é¼­ ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼­ ¿Â¶óÀÎ ¼­ºñ½ºÀÇ ¸Å·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - Áö¸®Àû ÅëÂû

ºÏ¹Ì´Â Á¤±³ÇÑ ÇコÄɾî ÀÎÇÁ¶ó¿Í ÃÖ÷´Ü À¯ÀüÀÚ °Ë»ç ±â¼úÀÇ ±¤¹üÀ§ÇÑ µµÀÔ¿¡ ÈûÀÔ¾î À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀåÀÇ È®´ë¸¦ À̲ø°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÁÖ¿ä »ê¾÷ ±â¾÷ÀÇ Å« Á¸Àç°¨, Ȱ¹ßÇÑ R&D ÀÌ´Ï¼ÅÆ¼ºê ¹× Áö¿ø ±ÔÁ¦ ȯ°æÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. °Ô´Ù°¡ ¼ÒºñÀÚÀÇ ÀÇ½Ä Áõ°¡, ¼ÒºñÀÚ Á÷Á¢(DTC) À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±Ù, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ¸ÞµðÄÉ¾î ¹× ¸ÞµðÄÉÀÌµå ¼­ºñ½º¼¾ÅÍ º¸°í¿¡ µû¸£¸é ¹Ì±¹ ÀÇ·áºñ´Â 2023³â 7.5% Áõ°¡ÇßÀ¸¸ç ÃÑ¾× 4Á¶ 9,000¾ï ´Þ·¯, °³Àδç 14,570´Þ·¯¿¡ ÇØ´çÇÏ¸ç ±¹³»ÃÑ»ý»ê(GDP)ÀÇ 17.6%¸¦ Â÷ÁöÇÕ´Ï´Ù. À¯·´Àº È®¸³µÈ ÇコÄÉ¾î ½Ã½ºÅÛ, Áøº¸µÈ Áø´Ü ±â¼úÀÇ ÀÌ¿ë·ü »ó½Â, Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¿¹¹æ¿¡ °­ÇÑ °ü½É µîÀÇ ÀåÁ¡À» ´©¸®°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - °æÀï ±¸µµ :

À¯Àü °Ë»ç ¼­ºñ½º ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ¸ç ±âÁ¸ ÀÓ»ó °Ë»ç ±â°ü, »ý¸í °øÇÐ ±â¾÷, ½ÃÄö½Ì ±â¼ú °ø±ÞÀÚ, ½Å±Ô DTC(Direct-to-Consumer) À¯ÀüÀÚ °Ë»ç ±â¾÷ µî ´Ù¾çÇÑ ±â¾÷ÀÌ Âü°¡Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ÁøÃâ ±â¾÷Àº Â÷¼¼´ë ½ÃÄö¼­(NGS), ÀΰøÁö´É(AI) ÁÖµµÀÇ µ¥ÀÌÅÍ ºÐ¼®, Ŭ¶ó¿ìµå ±â¹ÝÀÇ ¸®Æ÷ÆÃ Ç÷§Æû¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÁöÀ§¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ ±â¾÷Àº ¼­ºñ½º ³»¿ëÀ» È®´ëÇϰí Á¾¾çÇÐ, »ý½Ä ÀÇ·á, ¾à¸® À¯ÀüüÇÐ, Èñ±Í À¯Àü¼º ÁúȯÀÇ Áø´Ü¿¡ ÀÀ¿ëÀ» Æ÷ÇÔÇÏ·Á°íÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ º¯È­´Â ±â¼ú Çõ½Å, Á¢±Ù¼º, Á¾ÇÕÀûÀÎ À¯Àüü ¼Ö·ç¼Ç¿¡ ´ëÇÑ °­ÇÑ ÁÖ·ÂÀ» °­Á¶ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½ºÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º »ê¾÷ÀÇ Á¶»ç

Á¦5Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå »óȲ

Á¦7Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - Á¦Ç° À¯Çü

Á¦8Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - ¿ëµµº°

Á¦9Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - ¼­ºñ½º Á¦°ø¾÷üº°

Á¦10Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - À¯Åë ä³Îº°

Á¦11Àå À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - À¯ÀüÀÚ °Ë»ç ¼­ºñ½º ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Genetic Testing Services Market size was valued at US$ 11,897.56 Million in 2024, expanding at a CAGR of 22.4% from 2025 to 2032.

Genetic testing services entail the examination of an individual's DNA, chromosomes, or proteins to identify genetic variations associated with specific diseases or conditions. These tests fulfil various roles, such as diagnosis, carrier screening, prenatal testing, and predictive evaluations. In medical environments, they are extensively utilized for diagnosing diseases, assessing risks, planning treatments, and implementing preventive measures. Furthermore, the emergence of direct-to-consumer (DTC) services has broadened their application to include areas like ancestry research and wellness insights. Genetic testing can be performed at different life stages prenatal, newborn, or adult, and includes a variety of techniques, such as carrier testing, pharmacogenomic testing, and predictive testing. While genetic testing provides significant insights, it is crucial to weigh its advantages, limitations, and the potential consequences of the findings. The growing focus on early detection, personalized medicine, and preventive healthcare continues to propel the worldwide expansion of genetic testing services.

Genetic Testing Services Market- Market Dynamics

Increased Prevalence of Genetic Disorders is anticipated to drive the growth of the market.

As awareness of inherited conditions increases and advancements in genetic science progress, a growing number of individuals are pursuing early diagnosis and tailored treatment options through genetic testing. This trend is further bolstered by enhanced accessibility to testing services, an increasing demand for preventive healthcare, and the incorporation of genetic insights into clinical decision-making. Genetic disorders and congenital abnormalities are present in approximately 2%-5% of all live births, contribute to up to 30% of pediatric hospital admissions, and are responsible for around 50% of childhood deaths in industrialized nations, as reported by the World Health Organization. Nevertheless, ongoing innovations in next-generation sequencing (NGS), CRISPR, and bioinformatics may present growth opportunities for the market. Furthermore, the high costs associated with testing and equipment could hinder market growth.

Genetic Testing Services Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 22.4% over the forecast period (2025-2032)

Based on product type segmentation, Newborn Screening was predicted to show the maximum market share in the year 2024

Based on Service Provider segmentation, Hospitals & Clinics were the leading Service Provider in 2024

Based on Distribution Channel segmentation, online was the leading Distribution Channel in 2024

Based on region, North America was the leading revenue generator in 2024

Genetic Testing Services Market- Segmentation Analysis:

The Global Genetic Testing Services Market is segmented based on Product Type, Application, Service Provider, Distribution Channels, and Region.

The market is segmented into four categories according to product type: Prenatal Testing, Newborn Screening, Predictive and Presymptomatic Testing, Pharmacogenomics Testing, and Others. Newborn Screening is the primary driver of market growth. This segment leads the Genetic Testing Services market due to its essential function in the early identification of genetic, metabolic, and congenital disorders shortly after birth. It dominates the market as governments and healthcare organizations globally mandate or strongly advocate for these screenings to facilitate prompt diagnosis and timely treatment, thus preventing long-term complications or fatalities. Advancements in technology related to genetic testing methods, such as tandem mass spectrometry and next-generation sequencing, have further improved the precision and breadth of newborn screening.

The market is categorized into three segments based on their applications: Oncology, Infectious Diseases, Autoimmune Diseases, and Others. Genetic testing in the field of oncology facilitates the detection of inherited cancer syndromes, specific mutations in tumors, and the assessment of responses to targeted therapies, thereby significantly enhancing treatment outcomes. Following oncology, the infectious diseases sector is experiencing rapid growth due to the heightened demand for precise and swift pathogen detection, especially during global health emergencies such as the COVID-19 pandemic. Autoimmune diseases also play a significant role in the market, as genetic testing aids in comprehending individual susceptibility and customizing immunomodulatory treatments. The others category encompasses applications related to cardiovascular disorders, neurological conditions, and rare genetic diseases, which are continually expanding as awareness and diagnostic capabilities advance.

The market is segmented into three categories according to their Service Providers: Hospital-based Laboratories, Diagnostic Laboratories, Specialty Clinics, and Others. Hospital-based Laboratories are at the forefront of market growth. The growth of the Genetic Testing Services market is primarily driven by hospitals and clinics, which benefit from their extensive infrastructure, access to cutting-edge diagnostic technologies, and seamless integration with patient care pathways. These facilities frequently serve as the initial point of contact for individuals undergoing diagnostic assessments, facilitating prompt referrals and testing for genetic disorders such as cancer, rare diseases, and prenatal abnormalities. The increasing investments in hospital infrastructure, the rising adoption of personalized medicine, and partnerships with genetic testing providers are further enhancing the leadership of this segment in the market.

The market is categorized into two segments based on Distribution Channels: Online and Offline. The Online segment leads in market growth. The online segment significantly contributes to the expansion of the Genetic Testing Services market, mainly due to the rising demand for direct-to-consumer (DTC) genetic testing, as well as its convenience and accessibility. Online platforms enable users to order test kits, collect samples from the comfort of their homes, and receive results digitally, thus removing the necessity for in-person clinical visits. The increase in consumer awareness regarding genetic health, ancestry, and disease risk has enhanced the appeal of online services, particularly in developed markets.

Genetic Testing Services Market- Geographical Insights

North America continues to lead the expansion of the Genetic Testing Services market, bolstered by its sophisticated healthcare infrastructure and the widespread adoption of cutting-edge genetic testing technologies. This region is marked by the significant presence of key industry players, vigorous research and development initiatives, and a supportive regulatory environment. Furthermore, increasing consumer awareness, broad access to direct-to-consumer (DTC) genetic tests, and a growing demand for personalized medicine are propelling market growth. As reported by the Centers for Medicare & Medicaid Services, U.S. healthcare expenditures increased by 7.5% in 2023, totaling USD 4.9 trillion, equivalent to USD 14, 570 per individual and representing 17.6% of the country's Gross Domestic Product (GDP). Europe closely follows, reaping the benefits of well-established healthcare systems, rising utilization of advanced diagnostic technologies, and a strong focus on early disease detection and prevention.

Genetic Testing Services Market- Competitive Landscape:

The market for Genetic Testing Services is highly competitive, featuring a varied array of established clinical laboratories, biotechnology firms, sequencing technology providers, and new direct-to-consumer (DTC) genetic testing companies. Industry participants are making significant investments in next-generation sequencing (NGS), artificial intelligence (AI)-driven data interpretation, and cloud-based reporting platforms to enhance their positions in the market. To maintain competitiveness, businesses are expanding their service offerings to encompass applications in oncology, reproductive health, pharmacogenomics, and diagnostics for rare genetic disorders. This changing environment underscores a strong focus on innovation, accessibility, and comprehensive genomic solutions.

Recent Developments:

On May 6, 2025, Roche announced the introduction of its Elecsys PRO-C3 test, a novel diagnostic tool aimed at evaluating the severity of liver fibrosis in patients exhibiting symptoms of metabolic dysfunction-associated steatotic liver disease (MASLD).

On February 9, 2022, Genetic Testing Services Joint Stock Company (GENTIS) made an official announcement regarding its membership in the Eurofins Group, the largest medical group globally, thus becoming a foreign-invested enterprise. The two parties executed cooperation agreements and formally declared Gentis's integration into the Eurofins Group, marking its status as a foreign-invested medical enterprise.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENETIC TESTING SERVICES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL GENETIC TESTING SERVICES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TESTING SERVICES MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TESTING SERVICES MARKET, BY SERVICE PROVIDER- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TESTING SERVICES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TESTING SERVICES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Genetic Testing Services Market Overview

2. Executive Summary

3. Genetic Testing Services Key Market Trends

4. Genetic Testing Services Industry Study

5. Genetic Testing Services Market: Impact of Escalating Geopolitical Tensions

6. Genetic Testing Services Market Landscape

7. Genetic Testing Services Market - By Product Type

8. Genetic Testing Services Market - By Application

9. Genetic Testing Services Market - By Service Provider

10. Genetic Testing Services Market - By Distribution Channel

11. Genetic Testing Services Market- By Geography

12. Key Vendor Analysis- Genetic Testing Services Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â